Table 4.
Selection of current A2AR/CD73 inhibitor clinical trials. Information sourced from ClinicalTrials.gov.
| Trial | Aim | Target molecules | Condition | Phase |
|---|---|---|---|---|
| NCT03454451 | To evaluate the safety, tolerability, and anti-tumor activity of CPI-006 as a single agent, in combination with A2AR inhibitor CPI-444 and in combination with pembrolizumab | CPI-006: CD23 and adenosine inhibitor CPI-444: A2AR inhibitor Pembrolizumab: humanized anti-PD-1 mAb | • Non-small cell lung Cancer (NSCLC) • Renal cell cancer • Colorectal cancer • Triple negative breast cancer • Cervical cancer • Ovarian cancer • Pancreatic cancer • Endometrial cancer • Sarcoma • Squamous cell Carcinoma of the head and neck • Bladder cancer • Metastatic castration Resistant prostate cancer |
I |
| NCT02503774 | To evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of MEDI9447 (oleclumab) alone and in combination with MEDI4736 (Durvalumab) in adult subjects with select advanced solid tumors | Oleclumab: human anti-CD73 mAb Durvalumab: human anti-PD-1 mAb | • Advanced solid malignancies • NSCLC |
I |
| NCT02655822 | To study the safety, tolerability, and anti-tumor activity of A2Ar inhibitor CPI-444 alone and in combination with atezolizumab | CPI-444: A2AR inhibitor Atezolizumab: humanized anti-PD-1 mAb | • Non-small cell lung cancer • Malignant melanoma • Renal cell cancer • Triple negative breast cancer • Colorectal cancer • Bladder cancer • Metastatic • Castration resistant Prostate cancer |
I |
| NCT02740985 | To determine the maximum tolerated dose of A2AR receptor antagonist AZD4635 in combination with durvalumab | Durvalumab: human anti-PD-1 mAb AZD4635: A2AR receptor antagonist | • Advanced solid malignancies • NSCLC • Metastatic castrate-resistant prostate carcinoma • Colorectal carcinoma |
I |
| NCT03549000 | To assess the safety, tolerability, and anti-tumor activity of anti-CD73 NZV930 alone and when combined with anti-PD1 and/or A2AR inhibitor NIR178 | NZV930: anti-CD73 NIR178: A2AR inhibitor PDR001: experimental anti-PD-1 | • NSCLC • Triple negative breast cancer • Pancreatic ductal adenocarcinoma • Colorectal cancer microsatellite stable • Ovarian cancer • Renal cell carcinoma |
I |
| NCT02403193 | To determine the safety, tolerability, feasibility and efficacy of A2AR inhibitor PBF-509 alone and in combination with anti-PD1 | PBF-509: A2AR inhibitor PDR001: experimental anti-PD-1 | NSCLC | I/II |
| NCT03381274 | To evaluate the safety, tolerability and antitumor activity of novel combination therapies (oleclumab, A2AR inhibitor AZD4635 and osimertinib) | Oleclumab: human anti-CD73 mAb AZD4635: A2AR inhibitor Osimertinib: tyrosine kinase inhibitor | NSCLC | I/II |
| NCT03207867 | To evaluate the efficacy and safety of A2AR antagonist (NIR178) in combination with anti-PD1 | NIR178: A2AR inhibitor PDR001: experimental anti-PD-1 | • NSCLC • Renal cell cancer • Pancreatic cancer • Urothelial cancer • Head and neck cancer • Diffused large B cell • Lymphoma • Microsatellite stable colon cancer • Triple negative breast cancer • Melanoma |
II |